This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.
Study Type
OBSERVATIONAL
Enrollment
2,500
No intervention, observation study
Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University
Hangzhou, Zhejiang, China
RECRUITINGOverall survival
The duration from transplant until death resulted from any cause.
Time frame: From date of transplantuntil the date of death from any cause, assessed up to 60 months.
Relapse-free survival
The time from transplant until death or relapse.
Time frame: From date of transplant until the date of relapse or death from any cause, assessed up to 60 months.
Cumulative incidence of relapse
The time interval between the transplant and the occurrence of relapse.
Time frame: From date of transplant until the date of relapse, assessed up to 60 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.